TABLE 1.

Cohort prevalence estimates^a

Trait	Percent positivity by period (mo/day) (%)				Bayesian hierarchical model prevalence estimates by period (mo/day) (%)
	4/19–6/20	6/21–8/22	8/23–10/24	10/25–12/26	4/19–6/20		6/21–8/22		8/23–10/24		10/25–12/26
					Estimate	95% CI	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
Overall	5.4	11.8	10.9	13.9	2.9	1.8–4.5	10.2	8.5–12.2	9.1	7.2–11.2	12.8	10.6–15.2
Age (yrs)
5–17	4.2	9.7	8.4	12.1	1.9	0.5–4.3	8.0	3.9–13.2	6.8	2.8–11.9	11.4	6.3–17.4
18–49	5.9	13.4	10.9	15.5	3.5	2.1–5.3	12.1	9.5–14.8	9.1	6.3–12.0	14.5	11.1–18.0
50–64	5.9	12.4	12.5	12.7	3.8	2.1–5.8	10.9	8.4–13.7	11.1	8.2–14.3	11.3	8.0–14.8
65–99	4.6	10.2	10.1	13.7	1.7	0.3–3.7	8.4	6.3–10.8	8.1	5.5–10.9	12.7	9.5–16.2
Sex
Female	4.6	11.9	10.1	14.9	2.2	1.1–3.7	10.4	8.3–12.6	8.1	5.8–10.5	13.9	11.2–16.7
Male	6.4	11.5	11.9	12.5	3.9	2.3–5.9	10.1	7.9–12.3	10.5	8.0–13.1	11.3	8.5–14.3
Race/ethnicityb
NL White	3.8	8.2	8.8	10.5	1.5	0.5–2.8	6.2	4.4–8.1	6.7	4.6–8.9	9.0	6.7–11.5
NL Black	5.6	13.9	12.9	17.1	2.5	0.6–4.9	12.7	9.7–15.8	11.6	8.3–15.1	16.3	12.2–20.8
NL Other	5.7	12.3	12.0	12.9	2.1	0.1–6.0	10.8	6.2–16.4	9.9	5.1–15.4	11.4	6.3–17.3
Latinx	16.6	34.0	21.2	33.5	15.3	10.9–20.2	35.7	29.2–42.7	20.7	14.4–27.8	35.0	26.7–43.8
In-/outpatient
Outpatient	4.5	10.1	8.3	12.0	2.1	1.1–3.5	8.3	6.4–10.2	6.1	4.1–8.3	10.7	8.4–13.0
Inpatient	7.6	16.0	16.0	19.1	4.9	2.9–7.3	15.2	12.3–18.2	15.2	12.0–18.6	18.5	14.6–22.8
Payor
Private	5.2	9.8	9.3	12.1	2.9	1.5–4.6	8.2	6.1–10.6	7.6	5.2–10.2	10.9	8.1–13.8
Public	5.2	11.1	10.9	14.0	2.5	1.2–4.3	9.4	7.4–11.6	9.1	6.9–11.6	12.9	10.2–15.8
Self-pay	4.5	20.9	16.3	19.3	2.0	0.4–4.4	20.7	15.1–26.7	15.0	8.7–22.2	19.2	12.2–27.2
Other/unknown	21.7	38.2	36.4	46.2	20.8	11.6–31.2	38.9	26.8–52.2	34.9	16.8–55.7	46.6	27.9–66.5

^aRaw seropositivity (%) and posterior mean seroprevalence estimates (%) from our Bayesian hierarchical model with 95% credible intervals (lower bound, upper bound).

^bNL, non-Latinx.